Henk Portengen

The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.

John A. Foekens, Harry A. Peters, Maxime P. Look et al. · PubMed · 2000 · 429 citations

Tumor Biology, Breast Oncology, Oncology +14

Molecular Classification of Tamoxifen-Resistant Breast Carcinomas by Gene Expression Profiling

Maurice P.H.M. Jansen, John A. Foekens, Iris L. van Staveren et al. · Journal of Clinical Oncology · 2005 · 331 citations · Full text

Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer.

John A. Foekens, Henk Portengen, W L van Putten et al. · PubMed · 1989 · 219 citations

Epidermal Growth Factor, Breast Oncology, Growth Hormone +14

c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer.

E. Berns, J.G.M. Klijn, W L van Putten et al. · PubMed · 1992 · 206 citations

Her2/neu Genes, Breast Oncology, Medicine +13

Complete sequencing of TP53 predicts poor response to systemic therapy of advanced breast cancer.

E. Berns, John A. Foekens, R. van Vossen et al. · PubMed · 2000 · 197 citations

Breast Oncology, Pathology, Complete Sequencing +19